There are 2867 resources available
How to step up systems to better learn and manage new toxicities?
Presenter: Andreas Charalambous
Session: ESMO in collaboration with MASCC- Emerging toxicities to targeted therapies: Management strategies and future directions
Resources:
Slides
Webcast
728O - Results from phase I dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors
Presenter: Omid Hamid
Session: Proffered Paper session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
Conclusions and perspectives
Presenter: Emily Bergsland
Session: Challenging the use of small cell lung cancer as a paradigm for extrapulmonary neuroendocrine carcinoma
Resources:
Slides
Webcast
Invited Discussant LBA38 TBC and 728O
Presenter: David Braun
Session: Proffered Paper session: Investigational immunotherapy
Resources:
Slides
Webcast
Panel discussion on safety management of new anticancer drugs with case discussion and Q&A
Presenter: All Speakers
Session: ESMO in collaboration with MASCC- Emerging toxicities to targeted therapies: Management strategies and future directions
Resources:
Slides
Webcast
210O - Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET) +/- CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC)
Presenter: Antonio Marra
Session: Proffered Paper session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Discussion
Presenter: All Speakers
Session: Challenging the use of small cell lung cancer as a paradigm for extrapulmonary neuroendocrine carcinoma
Resources:
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session: Investigational immunotherapy
Resources:
Webcast
Conclusions
Presenter: Maryam Lustberg
Session: ESMO in collaboration with MASCC- Emerging toxicities to targeted therapies: Management strategies and future directions
Resources:
Slides
Webcast
LBA17 - Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC)
Presenter: Laurence Buisseret
Session: Proffered Paper session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast